Randomized controlled trial★ Featured study

Effects and safety of a CBD-richoil in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial - CANOA - cannabis for osteoarthritis.

Mojoli A, Haider O, Fakih Y, Luz Gonçalves MV, Zepeda Rojas B, Xaia G, et al. · Front Pharmacol · 2025

can-nabis read · published 2026-08-12

The read

The CANOA trial is one of the few properly blinded, placebo-controlled trials to test cannabidiol specifically for knee osteoarthritis, and it is worth including here precisely because it did not find what most CBD marketing promises. Researchers randomized osteoarthritis patients to a CBD-rich full-spectrum cannabis oil (45 mg of CBD daily) or a matched placebo, then tracked pain and function for 60 days using the WOMAC index, the standard tool for osteoarthritis trials.

At the end of the trial, the CBD group and the placebo group had improved by roughly the same amount. There was no statistically significant difference in pain intensity, and the secondary measures (mood, sleep quality, and physical and mental quality-of-life scores) showed the same pattern: both arms got a little better, and CBD did not pull ahead of placebo on any of them.

The safety data was clean. Nobody on CBD had a serious adverse event, and blood work showed no meaningful changes. That matters because it rules out one common counterargument, that CBD's real-world reports are held back by unsafe dosing. Here the dose was well tolerated and simply did not separate from placebo.

This does not settle the question. It tests one oil, one dose, one CBD-dominant ratio for one condition. Osteoarthritis pain trials in general have a strong placebo response, which can bury a real but modest effect. But if you are using a CBD-only product for joint pain and not feeling much beyond what a sugar pill might give you, this trial says you are not imagining that. The authors call for larger trials testing different doses and cannabinoid ratios, including THC, before writing off cannabinoids for osteoarthritis entirely.

What this paper found

45 mg/day of CBD-rich full-spectrum oil vs. placebo, 60 days, knee osteoarthritis patients, using the WOMAC pain index as the primary outcome.
No statistically significant difference in pain intensity between the CBD and placebo groups at trial end.
Secondary measures (sleep quality, mood, physical and mental quality of life) also showed no advantage for CBD over placebo.
Well tolerated: no serious adverse events and no meaningful changes in blood biomarkers.

Where it falls short

Tests one specific oil, dose, and CBD-dominant ratio. Does not address THC-containing or higher-dose products.
Osteoarthritis pain trials generally show a strong placebo response, which can obscure a real but modest drug effect.
60-day trial. Longer-term use, which is how most people actually take a daily CBD product, is not addressed.
Authors explicitly call for larger, multi-center trials with different doses and cannabinoid ratios before drawing firm conclusions.

Original abstract

UNLABELLED: Osteoarthritis is a common inflammatory and degenerative joint disease characterized by associated chronic pain, often ensuing to diminished quality of life. Current pain management options present small benefits and great side effects, driving interest in potential treatments such as cannabis, for its anti-inflammatory and analgesic effects. This trial aimed to assess the efficacy and safety of cannabidiol (CBD) in a full-spectrum cannabis oil in managing osteoarthritis-related pain. METHODS: Osteoarthritis patients were randomized into either placebo or cannabis groups and monitored for 60 days. The cannabis group received a CBD daily oral dose of 45 mg. Primary outcome was determined by pain intensity measured utilizing the WOMAC, while secondary outcomes included the Visual Analogue Scale (VAS) Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI) and the MC S12/PC S12 scores (mental and physical components of the quality of life SF-12 scale). RESULTS: At the end of intervention (i.e. 60 days or trial end-point), both the placebo and cannabis groups exhibited comparable improvements in pain scores, with no statistically significant differences in pain intensity observed between groups. Likewise, secondary outcomes showed no significant differences between groups. Furthermore, the CBD-rich cannabis oil was well-tolerated, as no patients experienced any serious adverse events or clinically significant changes in serum biomarkers. CONCLUSION: CBD-rich cannabis oil treatment was well tolerated, with no serious adverse effects observed. However, this treatment did not demonstrate superiority over placebo in alleviating pain or improving secondary outcomes in osteoarthritis patients. Further multicentrical and larger trials are warranted to explore the efficacy of alternative dosages and/or formulations containing CBD, THC and other cannabinoids. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT06588972 Identifier: [NCT06588972].

Read the source

Tagged conditions

Chronic pain →Sleep disorders →